Table 3.

Cox Regression analyses pertaining to 5- and 10-year cause-specific survival (CSS) and overall survival (OS) for patients diagnosed with IDC-P between 2000 and 2020

Variable	Cause-specific survival (CSS)				Overall survival (OS)
	Five-year (5y)		Ten-year (10y)		5y		10y
	Hazard Ratio (HR)	p-value	HR	p-value	HR	p-value	HR	p-value
Age >  = 65 / < 65 years	0.65	0.053	0.74	0.11	0.60	0.009	0.54	< 0.001
Race	N/A	0.43	N/A	0.24	N/A	0.99	N/A	0.32
Summary stage	N/A	< 0.001	N/A	< 0.001	N/A	< 0.001	N/A	< 0.001
Distant / (Local & Regional)	4.29	< 0.001	3.13	< 0.001	2.84	< 0.001	2.16	< 0.001
Local / (Regional & Distant)	0.46	0.010	0.46	0.002	0.66	0.065	0.70	0.045
Definitive surgery Y/N	1.70	0.37	2.69	0.051	2.50	0.064	4.11	< 0.001
Treatment only with surgery Y/N	3.29	0.033	3.70	0.005	2.32	0.08	1.88	0.085
Treatment with radiotherapy (RT) only Y/N	1.49	0.35	1.61	0.20	2.14	0.025	2.16	0.005
Type of RT	N/A	0.95	N/A	0.89	N/A	0.94	N/A	0.95
Chemotherapy Y/N	0.74	0.41	0.83	0.60	0.67	0.23	0.71	0.30
Regional lymph nodes surgically removed	N/A	0.66	N/A	0.58	N/A	0.25	N/A	0.60

Bivariate categorical variables have a HR listed, while variables with more than two categories have the overall p-value listed. Type RT has the following categories: Brachytherapy, External Beam Radiotherapy (EBRT), Radioisotopes, and Combination of EBRT and either Brachytherapy or Radioisotopes (based on coding in the SEER database). Definitive surgery was considered surgery with curative intent and included radical or total prostatectomy and pelvic exenteration, while local treatments such as laser ablation and transurethral resection of the prostate (TURP) were not